
Over the last 7 days, the Clinical Research and Equipment industry has risen 4.0%, driven by gains from Locus Cell of 24%. During this same period, the HeXun Biosciences underperformed, falling 7.0%. The industry has been flat over the past 12 months despite the gain this week.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 23 Jun 2026 | NT$32.6b | NT$2.7b | -NT$747,832,000.00 | 20.3x | -43.6x | 12.3x |
| Thu, 21 May 2026 | NT$32.0b | NT$2.7b | -NT$746,869,000.00 | 20.9x | -42.8x | 12.1x |
| Sat, 18 Apr 2026 | NT$34.7b | NT$2.5b | -NT$767,980,000.00 | 21.7x | -45.2x | 13.9x |
| Mon, 16 Mar 2026 | NT$31.4b | NT$2.5b | -NT$747,966,000.00 | 19.8x | -42x | 12.5x |
| Wed, 11 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Fri, 09 Jan 2026 | NT$34.0b | NT$2.4b | -NT$689,929,000.00 | 25x | -49.3x | 14x |
| Sun, 07 Dec 2025 | NT$37.9b | NT$2.4b | -NT$670,921,000.00 | 19.6x | -56.5x | 15.5x |
| Tue, 04 Nov 2025 | NT$35.5b | NT$2.5b | -NT$870,437,000.00 | 18.3x | -40.8x | 14.5x |
| Thu, 02 Oct 2025 | NT$38.7b | NT$2.5b | -NT$870,437,000.00 | 19.6x | -44.5x | 15.8x |
| Sat, 30 Aug 2025 | NT$34.9b | NT$2.5b | -NT$819,216,000.00 | 20.7x | -42.7x | 14.2x |
| Mon, 28 Jul 2025 | NT$34.9b | NT$2.5b | -NT$600,003,000.00 | 21.9x | -58.1x | 14.2x |
| Wed, 25 Jun 2025 | NT$33.7b | NT$2.5b | -NT$600,003,000.00 | 23.5x | -56.2x | 13.7x |
| Fri, 23 May 2025 | NT$31.9b | NT$2.5b | -NT$604,301,000.00 | 23x | -52.9x | 13x |
| Sun, 20 Apr 2025 | NT$31.6b | NT$2.5b | -NT$540,128,000.00 | 24.3x | -58.5x | 12.8x |
| Tue, 18 Mar 2025 | NT$36.7b | NT$2.6b | -NT$849,328,000.00 | 29.3x | -43.2x | 14.3x |
| Thu, 13 Feb 2025 | NT$37.0b | NT$2.6b | -NT$854,432,000.00 | 23.3x | -43.3x | 14.4x |
| Sat, 11 Jan 2025 | NT$36.5b | NT$2.6b | -NT$854,432,000.00 | 23.1x | -42.7x | 14.2x |
| Mon, 09 Dec 2024 | NT$40.7b | NT$2.6b | -NT$854,432,000.00 | 23.8x | -47.6x | 15.9x |
| Wed, 06 Nov 2024 | NT$43.0b | NT$2.5b | -NT$712,402,000.00 | 24.3x | -60.4x | 17.1x |
| Fri, 04 Oct 2024 | NT$41.9b | NT$2.3b | -NT$836,610,000.00 | 22.3x | -50x | 18.4x |
| Sun, 01 Sep 2024 | NT$41.6b | NT$2.3b | -NT$836,610,000.00 | 22.2x | -49.7x | 18.3x |
| Tue, 30 Jul 2024 | NT$41.7b | NT$2.1b | -NT$797,765,000.00 | 32.4x | -52.2x | 19.5x |
| Thu, 27 Jun 2024 | NT$42.0b | NT$2.1b | -NT$797,765,000.00 | 34.5x | -52.7x | 19.7x |
| Sat, 25 May 2024 | NT$39.8b | NT$2.1b | -NT$797,765,000.00 | 32.1x | -49.8x | 18.6x |
| Mon, 22 Apr 2024 | NT$38.2b | NT$2.1b | -NT$923,759,000.00 | 30x | -41.4x | 18.1x |
| Wed, 20 Mar 2024 | NT$40.4b | NT$2.1b | -NT$611,433,000.00 | 32.1x | -66.1x | 19.6x |
| Fri, 16 Feb 2024 | NT$43.3b | NT$2.1b | -NT$610,218,000.00 | 32.5x | -71x | 20.9x |
| Sun, 14 Jan 2024 | NT$44.9b | NT$2.1b | -NT$610,218,000.00 | 33.3x | -73.6x | 21.6x |
| Tue, 12 Dec 2023 | NT$48.7b | NT$2.1b | -NT$610,218,000.00 | 33.4x | -79.9x | 23.5x |
| Thu, 09 Nov 2023 | NT$49.3b | NT$2.2b | -NT$497,769,000.00 | 32.3x | -99.1x | 22.2x |
| Sat, 07 Oct 2023 | NT$48.3b | NT$2.2b | -NT$497,769,000.00 | 31.4x | -97.1x | 21.7x |
| Mon, 04 Sep 2023 | NT$43.9b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -88.2x | 19.7x |
| Wed, 02 Aug 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 43x | -176.3x | 19.8x |
| Fri, 30 Jun 2023 | NT$51.0b | NT$2.5b | -NT$274,767,000.00 | 43.2x | -185.7x | 20.8x |
-185.7x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 5.16% | |
| Healthcare | 6.79% | |
| Life Sciences | 4.03% | |
| Clinical Research and Equipment | 4.03% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$52.90 | 24.2% +NT$2.1b | 151.9% | PS830.8x | |
| 6589 EirGenix | NT$46.65 | 3.7% +NT$499.8m | -27.2% | PS12.5x | |
| 6661 Welgene BiotechLtd | NT$17.60 | 10.0% +NT$37.3m | -14.6% | PS1.1x | |
| 6848 RBC Bioscience | NT$19.95 | 0.3% +NT$713.7k | 21.6% | PE12.1x |